GB0211261D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0211261D0
GB0211261D0 GB0211261A GB0211261A GB0211261D0 GB 0211261 D0 GB0211261 D0 GB 0211261D0 GB 0211261 A GB0211261 A GB 0211261A GB 0211261 A GB0211261 A GB 0211261A GB 0211261 D0 GB0211261 D0 GB 0211261D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0211261A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to GB0211261A priority Critical patent/GB0211261D0/en
Publication of GB0211261D0 publication Critical patent/GB0211261D0/en
Priority to CN 200810125629 priority patent/CN101305990B/en
Priority to EP08152489.4A priority patent/EP1944026B1/en
Priority to DK08152489.4T priority patent/DK1944026T3/en
Priority to JP2004505027A priority patent/JP5227492B2/en
Priority to KR1020127025694A priority patent/KR20120125398A/en
Priority to PL396723A priority patent/PL396723A1/en
Priority to US10/513,804 priority patent/US20050215531A1/en
Priority to PCT/EP2003/005125 priority patent/WO2003097028A1/en
Priority to NZ536513A priority patent/NZ536513A/en
Priority to DE60324416T priority patent/DE60324416D1/en
Priority to KR10-2004-7018417A priority patent/KR20050003460A/en
Priority to ES03730049T priority patent/ES2316758T3/en
Priority to KR1020107027288A priority patent/KR20100133027A/en
Priority to SI200331499T priority patent/SI1505959T1/en
Priority to ES08152489T priority patent/ES2428697T3/en
Priority to AU2003240655A priority patent/AU2003240655B2/en
Priority to DK03730049T priority patent/DK1505959T3/en
Priority to KR1020137019570A priority patent/KR20130088904A/en
Priority to SI200332293T priority patent/SI1944026T1/en
Priority to AT03730049T priority patent/ATE412408T1/en
Priority to TW097139649A priority patent/TWI341197B/en
Priority to RU2004136980/14A priority patent/RU2358717C2/en
Priority to KR1020117018300A priority patent/KR101299873B1/en
Priority to NZ560662A priority patent/NZ560662A/en
Priority to PT81524894T priority patent/PT1944026E/en
Priority to KR1020127004175A priority patent/KR20120025018A/en
Priority to TW092113223A priority patent/TWI340036B/en
Priority to BR0311173-3A priority patent/BR0311173A/en
Priority to CA2483594A priority patent/CA2483594C/en
Priority to PT03730049T priority patent/PT1505959E/en
Priority to PL03372103A priority patent/PL372103A1/en
Priority to CN038111942A priority patent/CN1652757B/en
Priority to MXPA04011384A priority patent/MXPA04011384A/en
Priority to EP08152484.5A priority patent/EP1955696B1/en
Priority to EP03730049A priority patent/EP1505959B1/en
Priority to ZA2004/08575A priority patent/ZA200408575B/en
Priority to IL164838A priority patent/IL164838A/en
Priority to NO20045312A priority patent/NO334074B1/en
Priority to HK05106241.9A priority patent/HK1073606A1/en
Priority to RU2008141369/15A priority patent/RU2426555C2/en
Priority to CY20091100091T priority patent/CY1108719T1/en
Priority to US12/420,913 priority patent/US20090209495A1/en
Priority to HK09104529.3A priority patent/HK1126127A1/en
Priority to JP2009289475A priority patent/JP2010100637A/en
Priority to RU2011113815/15A priority patent/RU2011113815A/en
Priority to NO20130106A priority patent/NO20130106L/en
Priority to JP2013009158A priority patent/JP2013136584A/en
Priority to IL229559A priority patent/IL229559A0/en
Priority to IL229550A priority patent/IL229550A0/en
Priority to US14/311,838 priority patent/US20140303257A1/en
Ceased legal-status Critical Current

Links

GB0211261A 2002-05-16 2002-05-16 Organic compounds Ceased GB0211261D0 (en)

Priority Applications (51)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds
CN 200810125629 CN101305990B (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
EP08152489.4A EP1944026B1 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
DK08152489.4T DK1944026T3 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
JP2004505027A JP5227492B2 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
KR1020127025694A KR20120125398A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
PL396723A PL396723A1 (en) 2002-05-16 2003-05-15 Application of the EDG receptor binding factors in neoplastic diseases
US10/513,804 US20050215531A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
PCT/EP2003/005125 WO2003097028A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
NZ536513A NZ536513A (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
DE60324416T DE60324416D1 (en) 2002-05-16 2003-05-15 USE OF EDG RECEPTOR BINDING AGENTS FOR CANCER THERAPY
KR10-2004-7018417A KR20050003460A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
ES03730049T ES2316758T3 (en) 2002-05-16 2003-05-15 USE OF EDG RECEIVER BINDERS IN CANCER.
KR1020107027288A KR20100133027A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
SI200331499T SI1505959T1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
ES08152489T ES2428697T3 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
AU2003240655A AU2003240655B2 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
DK03730049T DK1505959T3 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
KR1020137019570A KR20130088904A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
SI200332293T SI1944026T1 (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
AT03730049T ATE412408T1 (en) 2002-05-16 2003-05-15 USE OF EDG RECEPTOR BINDING INGREDIENTS FOR CANCER THERAPY
TW097139649A TWI341197B (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
RU2004136980/14A RU2358717C2 (en) 2002-05-16 2003-05-15 Application of edg-receptor binding agent in cancer therapy
KR1020117018300A KR101299873B1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
NZ560662A NZ560662A (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
PT81524894T PT1944026E (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
KR1020127004175A KR20120025018A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
TW092113223A TWI340036B (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
BR0311173-3A BR0311173A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
CA2483594A CA2483594C (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
PT03730049T PT1505959E (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
PL03372103A PL372103A1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
CN038111942A CN1652757B (en) 2002-05-16 2003-05-15 Use of EDG receptor binding agents in cancer
MXPA04011384A MXPA04011384A (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer.
EP08152484.5A EP1955696B1 (en) 2002-05-16 2003-05-15 Use of the EDG receptor binding agent FTY720 in cancer
EP03730049A EP1505959B1 (en) 2002-05-16 2003-05-15 Use of edg receptor binding agents in cancer
ZA2004/08575A ZA200408575B (en) 2002-05-16 2004-10-22 Use of edg receptor binding agents in cancer
IL164838A IL164838A (en) 2002-05-16 2004-10-25 Use of edg receptor binding agents in preparing a composition for treating cancer
NO20045312A NO334074B1 (en) 2002-05-16 2004-12-03 Use of an S1P receptor agonist
HK05106241.9A HK1073606A1 (en) 2002-05-16 2005-07-22 Use of edg receptor binding agents in cancer edg
RU2008141369/15A RU2426555C2 (en) 2002-05-16 2008-10-20 Application of medications, binding edg-receptor, in treatment of cancer disease
CY20091100091T CY1108719T1 (en) 2002-05-16 2009-01-27 USE OF FACTORS RELATED TO EDG CANCER
US12/420,913 US20090209495A1 (en) 2002-05-16 2009-04-09 Use of edg receptor binding agents in cancer
HK09104529.3A HK1126127A1 (en) 2002-05-16 2009-05-18 Use of edg receptor binding agents in cancer edg
JP2009289475A JP2010100637A (en) 2002-05-16 2009-12-21 Use of edg receptor-binding agent in cancer
RU2011113815/15A RU2011113815A (en) 2002-05-16 2011-04-11 APPLICATION OF MEDIA BINDING EDG RECEPTOR IN THE TREATMENT OF CANCER DISEASE
NO20130106A NO20130106L (en) 2002-05-16 2013-01-17 Use of EDG receptor binding agents in cancer
JP2013009158A JP2013136584A (en) 2002-05-16 2013-01-22 Use of edg receptor binding agents in cancer
IL229559A IL229559A0 (en) 2002-05-16 2013-11-21 Use of edg receptor binding agents in cancer
IL229550A IL229550A0 (en) 2002-05-16 2013-11-21 Use of edg receptor binding agents in cancer
US14/311,838 US20140303257A1 (en) 2002-05-16 2014-06-23 Use of EDG Receptor Binding Agents in Cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0211261A GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds

Publications (1)

Publication Number Publication Date
GB0211261D0 true GB0211261D0 (en) 2002-06-26

Family

ID=9936819

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0211261A Ceased GB0211261D0 (en) 2002-05-16 2002-05-16 Organic compounds

Country Status (2)

Country Link
CN (1) CN101305990B (en)
GB (1) GB0211261D0 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010300919A1 (en) * 2009-09-29 2012-03-22 Novartis Ag Dosage regimen of an S1P receptor modulator
CN102565253A (en) * 2010-12-16 2012-07-11 中国人民解放军第二军医大学 Micromolecular metabolite atlas as well as producing method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003739A1 (en) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Fibrosis inhibitors containing as the active ingredient sphingosine-1-phosphate receptor agonist or sphingosine-1-phosphate

Also Published As

Publication number Publication date
CN101305990B (en) 2013-06-19
CN101305990A (en) 2008-11-19

Similar Documents

Publication Publication Date Title
GB0203276D0 (en) Organic compounds
GB0202873D0 (en) Organic compounds
GB0209265D0 (en) Organic compounds
GB0205281D0 (en) Organic compounds
GB0209481D0 (en) Organic compounds
GB0203061D0 (en) Organic compounds
GB0211261D0 (en) Organic compounds
GB0202874D0 (en) Organic compounds
GB0204756D0 (en) Organic compounds
GB0209257D0 (en) Organic compounds
GB0206366D0 (en) Organic compounds
GB0201181D0 (en) Organic compounds
GB0209883D0 (en) Organic compounds
GB0209885D0 (en) Organic compounds
GB0201881D0 (en) Organic compounds
GB0207731D0 (en) Organic compounds
GB0207729D0 (en) Organic compounds
GB0207728D0 (en) Organic compounds
GB0207726D0 (en) Organic compounds
GB0207506D0 (en) Organic compounds
GB0207503D0 (en) Organic compounds
GB0207500D0 (en) Organic compounds
GB0207496D0 (en) Organic compounds
GB0206694D0 (en) Organic compounds
GB0207504D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)